Efficient production of first in class antimicrobial therapeutics from an integrated synthetic biology approach.

通过综合合成生物学方法高效生产一流的抗菌疗法。

• 批准号: 102147
• 金额: $ 25.5万
• 依托单位: INGENZA LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=102147
• 关键词: Efficient; production; first; class; antimicrobial

Antibiotic resistant bacteria kill over 25,000 people a year in Europe and threaten a return to a time when minor infections can be fatal and routine surgery poses high risks. With development pipelines empty, there is a critical need for novel therapies to kill antibiotic resistant bacteria and serve as scaffolds for derivatisation, diversification and enhancement of efficacy, which proved successful with drugs like penicillin. This project will develop an exciting new class of antimicrobial biologics that rapidly kill bacteria, at very low doses and have great potential to prevent or treat bacterial infections including those caused by resistant bacteria. However, the development of the primary targets is hampered by their very low production in the native host and synthetic production would be prohibitively expensive. This project aims to develop efficient, adaptable and scalable microbial production systems for this novel compound class, enabling their development into a new platform of effective antibiotics.

在欧洲，耐药细菌每年导致超过2.5万人死亡，并有可能重返轻微感染可能致命、常规手术构成高风险的时代。在研发管道空荡荡的情况下，迫切需要新的疗法来杀死抗生素耐药性细菌，并作为衍生化、多样化和增强疗效的支架，这在青霉素等药物中被证明是成功的。该项目将开发一种令人兴奋的新型抗菌生物制品，这种生物制品能够以非常低的剂量快速杀死细菌，并具有巨大的潜力来预防或治疗细菌感染，包括由耐药细菌引起的感染。然而，主要目标的开发因其在本地宿主中的产量非常低而受到阻碍，而且合成生产将昂贵得令人望而却步。该项目旨在为这一新型化合物类别开发高效、适应性和可扩展的微生物生产系统，使其能够发展成为有效抗生素的新平台。